• Baijin Life Science released its annual report for FY26, flagging weaker overall performance as jewellery demand fell, hit by US tariff-driven pricing pressure.
• Strategy pivot toward the local fine-jewellery market, aiming to offset an expected further drop in US-focused revenue.
• Skincare operations expanded brand promotion, started building a flagship beauty club, planned company-run beauty salons to push product adoption.
• Healthcare push broadened through strategic cooperation agreements spanning circular RNA technology, medical-device distribution, clinical cell therapy.
• Post year-end, the group agreed to form a Shanghai joint venture for clinical cell therapy, holding a 51% stake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baijin Life Science Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261981), on July 30, 2026, and is solely responsible for the information contained therein.